NASDAQ:SNGX - Soligenix Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.63
  • Forecasted Upside: 154.85 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.03
+0.30 (1.20%)

This chart shows the closing price for SNGX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Soligenix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SNGX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SNGX

Analyst Price Target is $2.63
▲ +154.85% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Soligenix in the last 3 months. The average price target is $2.63, with a high forecast of $3.75 and a low forecast of $1.50. The average price target represents a 154.85% upside from the last price of $1.03.

This chart shows the closing price for SNGX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Soligenix. This rating has held steady since July 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/26/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/24/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/25/2021Alliance Global PartnersLower Price TargetBuy$5.75 ➝ $3.75Low
6/1/2021B. RileyLower Price TargetNeutral$2.00 ➝ $1.50Low
1/28/2021B. RileyReiterated RatingHold$2.00High
12/31/2020B. RileyReiterated RatingNeutralN/A
12/23/2020Alliance Global PartnersLower Price TargetBuy$7.25 ➝ $5.75N/A
12/4/2020B. RileyInitiated CoverageBuy$4.00High
7/28/2020Dawson JamesDowngradeBuy ➝ Neutral$3.00 ➝ $2.00High
6/25/2020Maxim GroupInitiated CoverageBuy$4.00High
5/1/2020Maxim GroupInitiated CoverageBuy$4.00Low
12/4/2019Maxim GroupReiterated RatingBuy$4.00Medium
8/29/2019Maxim GroupReiterated RatingBuy$4.00High
5/16/2019Maxim GroupReiterated RatingBuy$4.00High
3/26/2019Maxim GroupSet Price TargetBuy$4.00High
12/6/2018Maxim GroupSet Price TargetBuy$4.00High
9/13/2018Maxim GroupReiterated RatingBuy$4.00Low
6/4/2018Maxim GroupReiterated RatingBuy$5.00Low
5/11/2018Maxim GroupSet Price TargetBuy$5.00Low
3/22/2018Maxim GroupSet Price TargetBuy$5.00High
3/16/2018HC WainwrightSet Price TargetHold$3.00Low
3/15/2018Maxim GroupSet Price TargetBuy$5.00Medium
1/31/2018HC WainwrightDowngradeBuy ➝ Neutral$5.50 ➝ $2.70Low
1/3/2018Maxim GroupSet Price TargetBuy$5.00Low
12/21/2017Maxim GroupSet Price TargetBuy$5.00Low
11/6/2017HC WainwrightReiterated RatingBuy$11.00 ➝ $5.50N/A
10/31/2017Maxim GroupSet Price TargetBuy$5.00N/A
10/24/2017Maxim GroupSet Price TargetBuy$5.00N/A
9/21/2017HC WainwrightReiterated RatingBuy$11.00Medium
9/20/2017Maxim GroupReiterated RatingBuy$5.00Low
8/14/2017HC WainwrightSet Price TargetBuy$11.00High
8/14/2017Maxim GroupBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.00High
7/27/2017HC WainwrightSet Price TargetBuy$11.00Low
7/27/2017Maxim GroupSet Price TargetBuy$4.00Medium
7/17/2017HC WainwrightInitiated CoverageBuy ➝ BuyHigh
6/19/2017Maxim GroupReiterated RatingBuy$4.00Low
5/22/2017Maxim GroupSet Price TargetBuy$4.00Medium
5/11/2017Maxim GroupSet Price TargetBuy$4.00Medium
5/3/2017Maxim GroupSet Price TargetBuy$4.00Low
3/27/2017Maxim GroupSet Price TargetBuy$4.00High
12/19/2016Maxim GroupBoost Price TargetBuy$3.00 ➝ $4.00N/A
(Data available from 9/23/2016 forward)

News Sentiment Rating

0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/25/2021
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/25/2021
  • 7 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/24/2021
  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
9/23/2021

Current Sentiment

  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
Soligenix logo
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare disease. It operates through Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses in the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions solutions comprises active development programs for RiVax, ricin toxin vaccine candidate and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.
Read More

Today's Range

Now: $1.03
Low: $1.02
High: $1.04

50 Day Range

MA: $1.00
Low: $0.90
High: $1.16

52 Week Range

Now: $1.03
Low: $0.85
High: $2.80

Volume

7,711 shs

Average Volume

2,364,441 shs

Market Capitalization

$41.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31

Frequently Asked Questions

What sell-side analysts currently cover shares of Soligenix?

The following Wall Street analysts have issued research reports on Soligenix in the last year: Alliance Global Partners, and B. Riley.
View the latest analyst ratings for SNGX.

What is the current price target for Soligenix?

2 Wall Street analysts have set twelve-month price targets for Soligenix in the last year. Their average twelve-month price target is $2.63, suggesting a possible upside of 154.9%. Alliance Global Partners has the highest price target set, predicting SNGX will reach $3.75 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $1.50 for Soligenix in the next year.
View the latest price targets for SNGX.

What is the current consensus analyst rating for Soligenix?

Soligenix currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SNGX will outperform the market and that investors should add to their positions of Soligenix.
View the latest ratings for SNGX.

What other companies compete with Soligenix?

How do I contact Soligenix's investor relations team?

Soligenix's physical mailing address is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. The biopharmaceutical company's listed phone number is (609) 538-8200 and its investor relations email address is [email protected] The official website for Soligenix is www.soligenix.com.